drugset / Trial / NCT00263666

A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa

NCT00263666

Phase 2 Completed 100 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The aim of this study is to evaluate the reactogenicity, safety and immunogenicity of GSK Biologicals' human rotavirus (HRV) vaccine given concomitantly with routine vaccines including OPV in HIV positive infants. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Timeline

Start
2005-03-16
Primary completion
2008-02-07
Completion
2008-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotarix Vaccine Oral
Background Polio Sabin Vaccine Oral
Background Tritanrix-HB+Hib Vaccine Intramuscular

Indications